FY25 consensus $270.48M. For 2025, Aurinia is increasing total revenue guidance from a range of $260 million to $270 million to a range of $275 million to $280 million and net product sales guidance from a range of $250 million to $260 million to a range of $265 million to $270 million.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Midday Fly By: AWS in deal with OpenAI, Kimberly-Clark to buy Kenvue
- Aurinia Pharmaceuticals to Announce Q3 2025 Financial Results and Business Update
- FDA official resigns, sued by Aurinia Pharmaceuticals, WSJ reports
- Aurinia Pharmaceuticals (AUPH) Q3 Earnings Cheat Sheet
- Aurinia Pharmaceuticals Advances Voclosporin Study in Young Lupus Nephritis Patients